{"query":"Differentiated Therapeutics Allen Bryce protein degradation news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://www.drugdiscoverychemistry.com/22/artificial-intelligence","title":"Artificial Intelligence for Early Drug Discovery | April 19-20, ...","content":"Bryce Allen, PhD, Co-Founder & CEO, Differentiated Therapeutics. Targeted Protein Degradation (TPD) is complex and only partially understood. In contrast to","score":0.6937432,"raw_content":null},{"url":"https://www.businesswire.com/news/home/20220729005078/en/Differentiated-Therapeutics-Raises-%245-Million-Seed-Round","title":"Differentiated Therapeutics Raises $5 Million Seed Round","content":"“Targeted protein degradation is an emerging therapeutic modality with tremendous potential to transform medicine, but a major limitation is the","score":0.6501347,"raw_content":null},{"url":"https://www.dxtherapeutics.com/about","title":"About Us","content":"## WE ARE ENGINEERING THE TARGETED PROTEIN DEGRADATION TOOLBELT TO EMPOWER A NEW PARADIGM OF DRUG DISCOVERY SCIENTISTS. Differentiated Therapeutics is pioneering the discovery, design, and optimization of novel protein degraders, that are designed to be disease-modifying and target the underlying cause of disease. Differentiated Therapeutics (dx/tx) is a protein degradation company focused on discovering and developing transformative medicines to treat patients with life-altering diseases. Our team integrates extensive biology knowledge and a drug hunter’s intuition leveraging our proprietary Auto/dx platform to deliver a robust pipeline spanning multiple molecular targets in various therapeutic areas; these combine together into something truly remarkable: end-to-end discovery capabilities and world-class collaborators in the field of protein degradation to propel us ahead in our mission. ### ANDREW ALLEN. ### STEPHANE BILLOTTE. ### STEPHANE CORBEL. ### ZAK KOHANE, MD, PhD. Co-founder, Chair of the Department of Biomedical Informatics, Harvard Medical School. ### PETER SICINSKI, MD, PhD. Professor of Genetics, Harvard Medical School.","score":0.6469293,"raw_content":null},{"url":"https://www.linkedin.com/company/dxtherapeutics","title":"Differentiated Therapeutics Inc","content":"Overview:\nDifferentiated Therapeutics (dx/tx) has built the first end-to-end discovery engine for Targeted Protein Degradation (TPD) which drives the discovery and optimization of novel protein degraders designed to eliminate the genetically defined drivers of disease\n\nWebsite: https://dxtherapeutics.com/\nCrunchbase Url: https://www.crunchbase.com/organization/differentiated-therapeutics?utm_source=linkedin&utm_medium=referral&utm_campaign=linkedin_companies&utm_content=profile_cta_anon&trk=funding_crunchbase\nLinkedin Url: https://www.linkedin.com/company/dxtherapeutics\n\nIndustry:\nBiotechnology Research\n\nCompany size:\n2-10 employees\n4 associated members (LinkedIn members who’ve listed Differentiated Therapeutics Inc as their current workplace on their profile)\n\nFounded:\n2021\n\nFunding:\nLast Round Date: 2022-09-01T00:00:00.000Z\nLast Round Type: Seed\nTotal Rounds: 1\nLast Round Raised: US$ 5.0M\n\nInvestors:\nCurie.Bio","score":0.50285697,"raw_content":null},{"url":"https://www.drugdiscoverychemistry.com/protein-degradation-molecular-glues","title":"Degraders & Molecular Glues Part 1 | April 14-15, 2026","content":"Image 9: Photo of Peichuan Zhang, Director, WuXi Biology, WuXi Apptec Co Ltd , Director , WuXi Biology , WuXi Apptec Co Ltd Peichuan Zhang, Director, WuXi Biology, WuXi Apptec Co Ltd. Targeted protein degradation (TPD) via the ubiquitin-proteasome system relies on specific E3 ligase complexes. Image 11 Matthew Perry, PhD, Director, Medicinal Chemistry, Halda Therapeutics Inc. Estrogen receptor (ER)-targeted RIPTACs selectively inactivate BRD4 in ER+ breast cancer, including post-CDK4/6i resistance settings. Image 15 Alessio Ciulli, PhD, Professor, Chemical & Structural Biology and Director of the Centre for Targeted Protein Degradation, University of Dundee. ### _Sponsored by:_ Exploration of Novel E3 Ligase to Support Targeted Protein Degradation Drug Discovery. Image 37: Photo of Alessio Ciulli, PhD, Professor, Chemical & Structural Biology and Director of the Centre for Targeted Protein Degradation, University of Dundee , Professor , Centre for Targeted Protein Degradation, , University of Dundee. Image 78,%20ubiquitin,%20protein%20degraders,%20PROTACs%20,%20molecular%20glues,%20induced%20proximity,%20chemoproteomics,%20ubiquitin%20ligases,%20cereblon%20binders,%20monovalent%20degraders,%20undruggable%20targets,%20drug%20discovery%20chemistry,%20medicinal%20chemistry,%20conference&p=https%3A%2F%2Fwww.drugdiscoverychemistry.com%2Fprotein-degradation-molecular-glues&r=&lt=763&evt=pageLoad&sv=2&cdb=AQAS&rn=862634).","score":0.18229482,"raw_content":null}],"response_time":1.18,"request_id":"b9daa513-7428-4d10-b9e1-be166ffedaaf"}